Tiotropium and olodaterol exert anti-proliferative effects on pulmonary fibroblasts of asthmatic patients in vitro Source: Annual Congress 2013 –Airway smooth muscle and cell biology Year: 2013
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: Eur Respir J 2015; 46: 1489-1492 Year: 2015
Tiotropium enhances the inhibitory effect of the long acting β2-agonist olodaterol on the release of IL-6 and IL8 by primary human lung fibroblasts of asthma patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Anti-inflammatory effect of hypoxic signaling suppression in the severe COPD model. Source: International Congress 2018 – COPD: novel pathological mechanisms in the airway epithelium Year: 2018
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Anti-inflammatory function of tiotropium mediated by suppression of acetylcholine-induced release of chemotactic activity Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The therapeutic effects of zafirlukast on COPD induced pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 415s Year: 2001
Antitussive and antiinflammatory effect of montelukast in patients with cough variant asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Source: Eur Respir J 2001; 17: 1059-1061 Year: 2001
Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
Nebulized bimosiamose – anti-inflammatory pan-selectin antagonist for the treatment of COPD Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Anti-inflammatory activity of doxofylline and theophylline in LPS-induced lung inflammation Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of RP6557, a dual PI3K d/? inhibitor, in glucocorticoid insensitive human neutrophils from chronic obstructive pulmonary disease patients Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
Combination of beta2 agonists and anticholinergic drugs improves lung function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 726s Year: 2006
PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014